The purpose of this study is to evaluate the safety and efficacy of IDE849 in participants with extensive stage small cell lung cancer (ES-SCLC), neuroendocrine carcinoma (NEC), and other delta-like protein 3 (DLL3)-expressing solid tumors.
The purpose of this study is to evaluate the safety and efficacy of IDE849 in participants with extensive stage small cell lung cancer (ES-SCLC), neuroendocrine carcinoma (NEC), and other delta-like protein 3 (DLL3)-expressing solid tumors.